SelectScience
Join Free
Accelerating Science
NewsDrug Discovery & Development

Abzena appoints Dr. Moncef Slaoui to board of directors

Abzena

With over 40 years of biopharma leadership experience, Dr. Slaoui will help drive innovation and growth for Abzena

13 Jan 2025

Industry news

Dr. Moncef Slaoui, Board of Directors, Abzena

Dr. Moncef Slaoui, Board of Directors, Abzena

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced the appointment of Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with over 40 years’ experience, Dr. Moncef Slaoui has held numerous executive leadership and board level positions, to help drug development companies through high phases of growth.

“I am thrilled to be joining Abzena’s Board of Directors,” said Dr. Slaoui. “Abzena is a true innovator in the CRO and CDMO space, and I look forward to helping them develop new technologies and platforms that enable the better delivery of next gen therapeutics.”

Dr. Slaoui currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio. He has previously sat on biotechnology company boards for Moderna, Inc., Lonza Group AG, Galvani, and Vaxcyte.

During the COVID-19 pandemic, he served as the Chief Scientific Advisor to Operation Warp Speed, where his leadership enabled the fastest manufacturing, approval and deployment of multiple COVID-19 vaccines in the US.

Dr. Slaoui spent three decades of his career at GlaxoSmithKline (GSK), where he held several senior leadership positions, including being a member of the Board of Directors of GSK PLC, Chairman of Pharmaceutical R&D, Chairman Global R&D, Vaccines & Oncology, and Chairman, Global Vaccines. During his tenure, he led GSK's Pharmaceutical R&D restructuring to improve its focus on innovation and productivity and was directly involved in the development of 14 new vaccines, including Shingrix, Cervarix, Mosquirix, Rotarix®, and Synflorix.

Dr. Slaoui holds a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles and completed his postdoctoral studies at Harvard Medical School and Tufts University. He also has an accelerated MBA from IMD in Switzerland.

Want more of the latest science news straight to your inbox? Become a member of SelectScience for free today>>

Links

AbzenaCompany website

Tags

Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.Vaccine DevelopmentVaccine development focuses on creating immunizations to protect against infectious diseases. The process involves identifying antigens, developing and testing vaccine efficacy, and ensuring safety through preclinical testing and multiple clinical trial phases. Scientists use various approaches, including weakened or inactivated viruses, protein subunits, or mRNA. Advanced platforms and rapid diagnostic tools aid in vaccine research and testing. Explore vaccine development solutions in our peer-reviewed product directory; compare products, read reviews, and get pricing directly from manufacturers.

Related articles

Abzena appoints Dr. Moncef Slaoui to board of directors